German radiopharma firm ITM has reported positive results from its phase 3 trial, potentially marking the first major success for radiopharmaceuticals in cancer treatment. The trial demonstrated that ITM-11, a targeted radiotherapy, can outperform traditional cancer treatments in patients suffering from inoperable, high-grade gastroenteropancreatic neuroendocrine tumors. The treatment combines a targeting molecule and a therapeutic radioactive isotope, significantly improving efficacy and safety.
UCDSB services still recovering after cyber incident: what parents and guardians need to know – Lanarkleedstoday.ca
The Upper Canada District School Board is still recovering from a cyber incident, causing disruptions to services. Parents and guardians should stay informed about the
